Jagsonpal Pharmaceutical Shares in Focus as Board to Consider Buyback Proposal on March 12
Shares of Jagsonpal Pharmaceutical Ltd. are drawing market attention on Tuesday, March 10, after the company announced that its board of directors will consider a proposal to buy back equity shares later this week.Board Meeting Scheduled to Review Share Buyback
Jagsonpal Pharmaceutical informed stock exchanges that its board will meet on March 12, 2026, to evaluate and potentially approve a proposal for the buyback of fully paid equity shares with a face value of ₹2 each.If the proposal is approved, it would mark the first share buyback in the company’s history, according to data available on the Bombay Stock Exchange.
Share buybacks typically involve a company repurchasing its own shares from the market, which can reduce the number of outstanding shares and potentially enhance shareholder value.
Corporate Actions Over the Years
Jagsonpal Pharma has undertaken several corporate actions in the past, including bonus issues and stock splits.In July 2004, the company issued bonus shares in a 3:1 ratio, granting shareholders three additional shares for every one share held on the record date.
More recently, in January 2025, the company implemented a stock split, dividing shares with a face value of ₹5 into shares with a face value of ₹2.
Dividend Track Record
The pharmaceutical company has also maintained periodic dividend payouts. Its most recent final dividend of ₹2.5 per share was declared in September 2025.Prior to that, Jagsonpal Pharma declared dividends of ₹5 per share in September 2024 and August 2023. In 2021, the company announced two dividends of ₹4 and ₹1 in October and September respectively.
Stock Performance
Jagsonpal Pharmaceutical shares ended the previous trading session at ₹169.05, down 2.5 percent.The stock has experienced pressure in recent months, falling 8.4 percent over the past month, 31 percent over the last six months, and 12.2 percent so far this year.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Last edited by a moderator: